awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q41092089-89871A2F-6090-4CE0-BCCB-20FA02979A66
Q41092089-89871A2F-6090-4CE0-BCCB-20FA02979A66
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41092089-89871A2F-6090-4CE0-BCCB-20FA02979A66
In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study.
P2860
Q41092089-89871A2F-6090-4CE0-BCCB-20FA02979A66
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41092089-89871A2F-6090-4CE0-BCCB-20FA02979A66
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
8f5a6e23042681a5c8adf5df3d4545bd72d39ed8
P2860
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.